07:55 AM EDT, 04/28/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Monday the European Commission granted conditional marketing approval for its experimental therapy, Lynozyfic, to treat adults with relapsed and refractory multiple myeloma.

The company said the approval was based on trial results showing a 71% objective response rate, with 50% of patients achieving a complete response or better.

In the US, the company said the Food and Drug Administration has accepted the marketing application for the therapy and is expected to decide by July 10.